midodrine

(redirected from ProAmatine)
Also found in: Medical.
Related to ProAmatine: Midodrine, Midodrine hydrochloride
Translations

midodrine

n midodrina
References in periodicals archive ?
M2 PHARMA-December 5, 2011-Shire agrees with CDER on ProAmatine approval path(C)2011 M2 COMMUNICATIONS
5 December 2011 - Shire Plc (LON:SHP), a UK-based biopharmaceutical company, said on Friday that under an agreement with the Centre for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) it will conduct additional clinical studies to confirm the benefit of ProAmatine (midodrine HCl) for the treatment of symptomatic orthostatic hypotension (SOH).
Midodrine received accelerated approval as ProAmatine in 1996 based on the surrogate end point of increase in 1-minute standing systolic blood pressure.
The drug manufacturer issued a statement that it will pull back ProAmatine by the end of September.
The Irish drugmaker said in a statement it will withdraw ProAmatine by the end of September.
M2 PHARMA-September 23, 2011-Shire provides update on ProAmatine approval status, availability in USA(C)2011 M2 COMMUNICATIONS
It has received approval for generic Proamatine (Shire Pharmaceuticals Group PLC), midodrine hydrochloride 2.
Shire Pharmaceuticals Group plc (Nasdaq:SHPGY) markets PROAMATINE for treatment of symptomatic orthostatic hypotension.
7 September 2010 - The US Food and Drug Administration (FDA)A is backing away from a plan to remove Shire PLC's (LON: SHP) low-blood-pressure treatment ProAmatine from the market, the Associated Press reported yesterday.